https://mindmedicinelaw.com/briefing/psychedelic-drug-market-gains-momentum-with-new-buy-signal-20260719-24254The Psychedelic Journalen2026-07-20T22:03:55.716036+00:00Psychedelic Drug Market Gains Momentum with New Buy Signalpsychedelic drug market, investor confidence, mental health treatment, clinical trials, FDA breakthrough therapy, regulatory oversight, psychedelic research, investment in psychedelics, mental health conditions, ethical considerationshttps://mindmedicinelaw.com/briefing/eeg-complexity-drop-in-dmt-sessions-implications-for-research-20260719-24020The Psychedelic Journalen2026-07-20T22:03:46.450858+00:00EEG Complexity Drop in DMT Sessions: Implications for ResearchEEG complexity, DMT sessions, psychedelic research, Lempel-Ziv complexity, non-stationary data, methodological adjustments, exploratory study, confirmatory replication, psychedelic EEG, research protocolshttps://mindmedicinelaw.com/briefing/eeg-complexity-dip-in-dmt-sessions-implications-for-research-20260719-24019The Psychedelic Journalen2026-07-20T15:05:13.183907+00:00EEG Complexity Dip in DMT Sessions: Implications for ResearchDMT, EEG complexity, psychedelic research, methodological rigor, Lempel-Ziv complexity, procedural factors, neuroscience, clinical trials, data exclusion, replicationhttps://mindmedicinelaw.com/briefing/psilocybin-dose-measurement-in-retreat-settings-new-insights-20260718-23624The Psychedelic Journalen2026-07-19T22:04:14.321062+00:00Psilocybin Dose Measurement in Retreat Settings: New Insightspsilocybin retreats, dose measurement, psilocybin variability, rapid assay, safety protocols, psilocybin standardization, natural product settings, psilocybin researchhttps://mindmedicinelaw.com/briefing/dmt-abort-tracker-enhances-cluster-headache-research-20260718-23659The Psychedelic Journalen2026-07-19T22:04:05.776252+00:00DMT Abort Tracker Enhances Cluster Headache ResearchDMT, cluster headache, clinical trials, psychedelic research, data collection, pharmacokinetics, adverse effects, patient education, longitudinal studyhttps://mindmedicinelaw.com/briefing/psilocybin-s-sex-specific-effects-in-schizophrenia-models-20260718-23625The Psychedelic Journalen2026-07-19T22:03:57.252975+00:00Psilocybin's Sex-Specific Effects in Schizophrenia Modelspsilocybin, schizophrenia, sex-specific effects, sensorimotor gating, mGlu5 knockout mice, glutamatergic dysfunction, serotonergic systems, psychiatric disorders, therapeutic strategies, clinical trialshttps://mindmedicinelaw.com/briefing/dmt-abort-tracker-advancing-cluster-headache-research-20260718-23658The Psychedelic Journalen2026-07-19T22:03:48.833499+00:00DMT Abort Tracker: Advancing Cluster Headache ResearchDMT, cluster headache, longitudinal data collection, clinical trials, psychedelic research, pharmacokinetics, PS27, adverse effects, personalized medicine, neurosciencehttps://mindmedicinelaw.com/briefing/visuomotor-mismatch-eeg-responses-implications-for-clinical-trials-20260717-23660The Psychedelic Journalen2026-07-20T22:04:19.203463+00:00Visuomotor Mismatch EEG Responses: Implications for Clinical Trialsvisuomotor mismatch, EEG responses, human cortex, clinical trials, neuroscience, prediction errors, translational research, visual feedback, wireless EEG, virtual realityhttps://mindmedicinelaw.com/briefing/visuomotor-mismatch-eeg-responses-new-insights-in-human-research-20260717-23662The Psychedelic Journalen2026-07-20T22:04:12.466333+00:00Visuomotor Mismatch EEG Responses: New Insights in Human Researchvisuomotor mismatch, EEG, virtual reality, predictive coding, sensory processing, clinical trials, neuroscience, human cortex, animal-human studies, wireless technologyhttps://mindmedicinelaw.com/briefing/combination-therapies-in-parkinson-s-research-new-avenues-20260717-23679The Psychedelic Journalen2026-07-20T22:04:05.411137+00:00Combination Therapies in Parkinson's Research: New Avenuesparkinson's disease, combination therapies, disease-modifying treatments, neurodegenerative research, clinical trials, oncology models, biomarkers in PD, FDA approvals, drug interactions, patient stratificationhttps://mindmedicinelaw.com/briefing/esketamine-s-limited-impact-on-bdnf-in-trd-clinical-insights-20260717-23669The Psychedelic Journalen2026-07-19T22:04:21.710058+00:00Esketamine's Limited Impact on BDNF in TRD: Clinical Insightsesketamine, treatment-resistant depression, BDNF, clinical trials, oral administration, psychedelic research, synaptic plasticity, antidepressant efficacy, biochemical pathways, depression treatmenthttps://mindmedicinelaw.com/briefing/ketamine-s-short-term-efficacy-for-sud-a-meta-analysis-insight-20260717-23626The Psychedelic Journalen2026-07-19T15:04:47.086532+00:00Ketamine's Short-Term Efficacy for SUD: A Meta-Analysis Insightketamine, substance use disorder, meta-analysis, clinical trials, short-term efficacy, safety concerns, treatment protocols, neuroscience, public health, randomized controlled trialshttps://mindmedicinelaw.com/briefing/fda-fast-tracks-psychedelic-research-following-executive-order-20260717-23744The Psychedelic Journalen2026-07-19T15:04:06.928167+00:00FDA Fast-Tracks Psychedelic Research Following Executive OrderFDA, psychedelic research, executive order, clinical trials, mental health, drug approval, Compass Pathways, Healing Pharmaceuticals, market dynamics, policy shifthttps://mindmedicinelaw.com/briefing/5-ht-2a-trkb-signaling-in-psychedelic-effects-implications-20260716-24078The Psychedelic Journalen2026-07-20T15:04:45.280851+00:005-HT(2A)-TrkB Signaling in Psychedelic Effects: Implications5-HT(2A) receptor, TrkB receptor, psychedelic effects, mental health therapies, serotonergic psychedelics, neuroplasticity, clinical trials, therapeutic efficacy, G protein signaling, neurotrophic signalinghttps://mindmedicinelaw.com/briefing/federal-investigation-targets-online-ketamine-sales-20260716-23747The Psychedelic Journalen2026-07-19T15:04:56.652769+00:00Federal Investigation Targets Online Ketamine Salesketamine, online sales, federal investigation, psychedelic regulation, DEA, FDA, controlled substances, public health, market impact, legal compliancehttps://mindmedicinelaw.com/briefing/psilocybin-s-role-in-enhancing-brain-synaptic-plasticity-20260715-23722The Psychedelic Journalen2026-07-19T22:03:39.610163+00:00Psilocybin's Role in Enhancing Brain Synaptic Plasticitypsilocybin, synaptic plasticity, mental health, neuroscience, clinical trials, regulatory policy, therapeutic effects, brain function, psychedelics, FDAhttps://mindmedicinelaw.com/briefing/fda-schedules-hearing-on-psychedelics-for-medical-use-20260715-23743The Psychedelic Journalen2026-07-19T15:04:19.577472+00:00FDA Schedules Hearing on Psychedelics for Medical UseFDA hearing, psychedelic therapies, medical approval, psilocybin, MDMA, mental health treatment, regulatory pathways, clinical trials, safety concerns, policy implicationshttps://mindmedicinelaw.com/briefing/fda-finalizes-psychedelics-guidance-easing-path-to-approval-20260714-24253The Psychedelic Journalen2026-07-20T22:03:36.506012+00:00FDA Finalizes Psychedelics Guidance, Easing Path to ApprovalFDA psychedelics guidance, psychedelic drug approval, clinical trials, regulatory landscape, psychedelic research, therapeutic access, safety and efficacy, policy implications, drug commercialization, psychedelic substanceshttps://mindmedicinelaw.com/briefing/fda-finalizes-psychedelic-trial-guidance-impacts-on-research-20260714-24082The Psychedelic Journalen2026-07-20T15:04:27.435168+00:00FDA Finalizes Psychedelic Trial Guidance: Impacts on ResearchFDA, psychedelic clinical trials, psilocybin, MDMA, mental health, regulatory framework, investment, innovation, safety protocols, ethical considerationshttps://mindmedicinelaw.com/briefing/fda-clarifies-mdma-and-psilocybin-trial-guidelines-20260714-23746The Psychedelic Journalen2026-07-19T15:04:29.647583+00:00FDA Clarifies MDMA and Psilocybin Trial GuidelinesFDA guidelines, MDMA trials, psilocybin research, psychedelic therapies, clinical trials, regulatory framework, psychedelic industry, safety protocols, market approval, mental health treatmentshttps://mindmedicinelaw.com/briefing/va-s-new-partnership-on-psychedelic-treatments-for-veterans-20260713-24084The Psychedelic Journalen2026-07-20T15:04:35.769104+00:00VA's New Partnership on Psychedelic Treatments for VeteransVA partnership, psychedelic treatments, veteran mental health, rapid-acting therapies, PTSD treatment, depression treatment, clinical trials, psychedelic research, mental health policy, veteran healthcarehttps://mindmedicinelaw.com/briefing/fda-s-final-guidance-on-psychedelic-trials-key-changes-20260713-23742The Psychedelic Journalen2026-07-19T15:04:37.709334+00:00FDA's Final Guidance on Psychedelic Trials: Key ChangesFDA guidance, psychedelic trials, clinical research, regulatory framework, safety standards, therapeutic endpoints, risk management, informed consent, psychedelic therapies, public healthhttps://mindmedicinelaw.com/briefing/ketamine-s-role-in-cancer-pain-management-new-insights-20260711-23711The Psychedelic Journalen2026-07-20T15:05:03.804503+00:00Ketamine's Role in Cancer Pain Management: New Insightsketamine, cancer pain, palliative care, systematic review, pain management, clinical guidelines, NMDA receptor, opioid alternative, patient safety, clinical trialshttps://mindmedicinelaw.com/briefing/epigenetic-insights-on-ketamine-mdma-policy-impacts-20260711-23736The Psychedelic Journalen2026-07-20T15:04:53.632574+00:00Epigenetic Insights on Ketamine & MDMA: Policy Impactsketamine, MDMA, epigenetics, psychoplastogens, mental health, clinical trials, therapeutic development, regulatory considerations, neuroscience